MDCM
CRL icon

Morgan Dempsey Capital Management’s Charles River Laboratories CRL Stock Holding History

Morgan Dempsey Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-237
Closed -$54K – 118
2020
Q3 		$54K Sell
237
-78
-25% -$16.2K 0.02% 77
2020
Q2 		$55K Buy
315
+131
+71% +$20.9K 0.02% 80
2020
Q1 		$23K Buy
+184
New +$27.6K 0.01% 127

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Morgan Dempsey Capital Management's CRL Position: Q4 2020 in Review

Morgan Dempsey Capital Management sold out of Charles River Laboratories (CRL) in Q4 2020, closing a stake of 237 shares — an estimated $54K sold.

Morgan Dempsey Capital Management first reported a position in CRL in Q1 2020 and held it in 3 quarters. The position peaked at $55K in Q2 2020. 538 funds tracked by Wall St. Rank hold CRL as of Q4 2020.

  • Morgan Dempsey Capital Management reported no remaining Charles River Laboratories position as of Q4 2020 after selling out during the quarter.
  • Morgan Dempsey Capital Management sold 237 Charles River Laboratories shares in Q4 2020, an estimated $54K.
  • Morgan Dempsey Capital Management first reported a position in Charles River Laboratories in Q1 2020 and held it in 3 quarters.
  • Morgan Dempsey Capital Management's Charles River Laboratories position peaked at $55K in Q2 2020.
  • 538 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2020.

Based on Morgan Dempsey Capital Management's 13F filing for Q4 2020, filed 10 Feb 2021.